文献速递前列腺癌

高强度聚焦超声前列腺消融:患者偏好信息的潜在作用文献综述

Prostate Ablation Using High Intensity Focused Ultrasound: A Literature Review of the Potential Role for Patient Preference Information.
PubMed 文献 · J Urol · 2018-04-24

本文综述了高强度聚焦超声(HIFU)用于前列腺癌组织消融的安全性与有效性证据,以及患者偏好信息。检索PubMed与灰色文献(含FDA报告)后发现,美国境内缺乏可用于临床决策的HIFU有效性数据(如总生存或前列腺癌特异生存),境外长期数据稀疏且结果不一,亦无前列腺癌患者对HIFU治疗的偏好数据。作者认为未来患者偏好研究可为患者、临床医生、器械开发者及监管者的获益-风险评估提供补充信息。

要点

  • 美国缺乏HIFU用于前列腺癌、可供临床决策的有效性数据。
  • 境外长期有效性数据稀疏且结局不一。
  • 尚无前列腺癌男性对HIFU治疗的患者偏好数据。

核心结论

  • 美国缺乏HIFU在前列腺癌人群中的长期肿瘤学数据,给临床医生、患者和FDA等利益相关方带来新挑战。
  • 未来针对HIFU的患者偏好研究可补充患者、临床医生及器械开发者的信息,并可供监管者用于此类治疗器械的获益-风险评估。

研究设计与样本

  • 文献综述:检索PubMed与灰色文献,包括FDA报告。
  • 检索内容为局部前列腺癌原发与挽救性HIFU的安全性和有效性数据,以及HIFU相关安全性和有效性结局的患者偏好信息。

主要发现

  • 未发现美国境内与临床决策相关的高强度聚焦超声有效性数据,如总生存或前列腺癌特异生存。
  • 美国境外的长期有效性数据稀疏,且结局存在差异。
  • 未发现针对前列腺癌男性HIFU治疗的患者偏好数据。

临床怎么用

  • 临床决策时应认识到HIFU在美国人群中缺乏长期肿瘤学有效性证据。
  • 与患者沟通HIFU时可说明相关患者偏好信息尚缺,需结合现有证据权衡。
  • 患者偏好信息可支持器械获益-风险评估,供监管与开发参考。

局限性

  • 检索到的美国境外长期有效性数据稀疏且结局不一,难以形成一致结论。
  • 缺乏前列腺癌患者对HIFU的偏好数据,无法评估患者对相关不良事件的耐受程度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The FDA (Food and Drug Administration) recently allowed the marketing of 2 high intensity focused ultrasound devices for prostate tissue ablation indications after previous rejections for a prostate cancer indication due to insufficient data on clinical effectiveness or direct patient benefit. We reviewed the safety and effectiveness of high intensity focused ultrasound and knowledge regarding patient preferences, such as tolerance for adverse events associated with high intensity focused ultrasound ablation of tissue, in men with prostate cancer. This may inform decision making for device developers and the FDA. MATERIALS AND METHODS: We searched PubMed® and gray literature, including FDA reports for relevant data on 1) the safety and effectiveness of primary and salvage high intensity focused ultrasound of localized prostate cancer in studies performed in or outside the United States and 2) patient preference information on high intensity focused ultrasound related safety and effectiveness outcomes. RESULTS: We found no high intensity focused ultrasound effectiveness data relevant to clinical decision making, such as overall or prostate cancer specific survival, in the United States. Long-term effectiveness data from outside the United States were sparse and outcomes varied. We also found no patient preference data on high intensity focused ultrasound treatment in men with prostate cancer. CONCLUSIONS: The lack of long-term high intensity focused ultrasound oncological data in an American population has brought new challenges to prostate cancer stakeholders, including clinicians, patients and the FDA. Patient preference information from future patient studies on high intensity focused ultrasound could provide additional information to patients, clinicians, and current and prospective device developers. In addition, it can be used by regulators in benefit-risk evaluations of this class of treatment devices.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Babalola O, Lee TJ, Viviano CJ, et al. Prostate Ablation Using High Intensity Focused Ultrasound: A Literature Review of the Potential Role for Patient Preference Information. J Urol. 2018. PMID: 29702099. doi:10.1016/j.juro.2018.04.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。